Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (451-460 of 740) with videos related to

Pageof 74
Sort By:
Cancers|September 28, 2023
Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE TrialLisa B Leypoldt, Maria Gavriatopoulou, Britta Besemer, et al.
Blood|January 30, 2019
High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myelomaAnjan Thakurta, Maria Ortiz, Pedro Blecua, et al.
Haematologica|September 28, 2014
Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myelomaMeletios A Dimopoulos, Robert Z Orlowski, Thierry Facon, et al.
Journal of Clinical Medicine|October 7, 2020
Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based InductionEvangelos Terpos, Ioannis Ntanasis-Stathopoulos, Gerasimos-Petros Papassotiriou, et al.
Cell Reports|August 5, 2021
Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipientsCristina Bergamaschi, Evangelos Terpos, Margherita Rosati, et al.
Blood|February 7, 2009
International prognostic scoring system for Waldenstrom macroglobulinemiaPierre Morel, Alain Duhamel, Paolo Gobbi, et al.
Proteomics|August 8, 2025
Proteomic Analysis of Bone Marrow CD138+ Cells to Identify Proteins Associated With the Response of Multiple Myeloma Patients to Commonly Used Therapeutic RegimensFoteini Paradeisi, Aggeliki Tserga, Vasiliki Lygirou, et al.
Clinical and Translational Science|June 26, 2020
Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple MyelomaXiaoyu Yan, Xu Steven Xu, Katja C Weisel, et al.
American Journal of Hematology|June 12, 2016
Proteasome inhibitor associated thrombotic microangiopathyJennifer C Yui, Jan Van Keer, Brendan M Weiss, et al.
Future Oncology (London, England)|January 24, 2025
A plain language summary of the ICARIA study, comparing isatuximab-pomalidomide- dexamethasone with pomalidomide- dexamethasone in people with multiple myelomaPaul G Richardson, Aurore Perrot, Jesus San-Miguel, et al.
Pageof 74

Showing results (451-460 of 740) with videos related to

Sort By:
Pageof 74
Cancers|September 28, 2023
Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE TrialLisa B Leypoldt, Maria Gavriatopoulou, Britta Besemer, et al.
Blood|January 30, 2019
High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myelomaAnjan Thakurta, Maria Ortiz, Pedro Blecua, et al.
Haematologica|September 28, 2014
Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myelomaMeletios A Dimopoulos, Robert Z Orlowski, Thierry Facon, et al.
Journal of Clinical Medicine|October 7, 2020
Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based InductionEvangelos Terpos, Ioannis Ntanasis-Stathopoulos, Gerasimos-Petros Papassotiriou, et al.
Cell Reports|August 5, 2021
Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipientsCristina Bergamaschi, Evangelos Terpos, Margherita Rosati, et al.
Blood|February 7, 2009
International prognostic scoring system for Waldenstrom macroglobulinemiaPierre Morel, Alain Duhamel, Paolo Gobbi, et al.
Proteomics|August 8, 2025
Proteomic Analysis of Bone Marrow CD138+ Cells to Identify Proteins Associated With the Response of Multiple Myeloma Patients to Commonly Used Therapeutic RegimensFoteini Paradeisi, Aggeliki Tserga, Vasiliki Lygirou, et al.
Clinical and Translational Science|June 26, 2020
Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple MyelomaXiaoyu Yan, Xu Steven Xu, Katja C Weisel, et al.
American Journal of Hematology|June 12, 2016
Proteasome inhibitor associated thrombotic microangiopathyJennifer C Yui, Jan Van Keer, Brendan M Weiss, et al.
Future Oncology (London, England)|January 24, 2025
A plain language summary of the ICARIA study, comparing isatuximab-pomalidomide- dexamethasone with pomalidomide- dexamethasone in people with multiple myelomaPaul G Richardson, Aurore Perrot, Jesus San-Miguel, et al.
Pageof 74